This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Autoimmune disease				
Multiple sclerosis (MS)	T cell receptor (TCR)	<p>Studies in mice suggest that a recombinant TCR ligand could treat MS. In mice with experimental autoimmune encephalitis (EAE) induced by two different peptides, the disease was reversed by a single recombinant ligand as long as its target T cells were present. Also in the EAE mice, three different TCR ligands lowered IL-17 production, increased IL-10 and IL-13 in splenocytes and decreased spinal cord inflammatory lesions. Next steps include determining the minimum concentration of target T cells needed to trigger the therapeutic effects in EAE.</p> <p>GlaxoSmithKline plc's AnergiX, which targets the TCR, is in Phase I testing to treat MS.</p> <p>SciBX 2(14); doi:10.1038/scibx.2009.566 Published online April 9, 2009</p>	Patent and licensing status unavailable	<p>Sinha, S. <i>et al. J. Neurosci.</i>; published online March 25, 2009; doi:10.1523/JNEUROSCI.5812-08.2009 Contact: Halina Offner, Portland Veterans Affairs Medical Center, Portland, Ore. e-mail: offnerva@ohsu.edu</p>